RxDoctor Payments DataLook up a doctor →

Reza Gamagami, MD

Surgery · New Lenox, ILNPI 1275517153

Payments from drug & device makers

$1,245,008in general payments, 2019–2025

Across 1,499 payments — averaging $830.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1.2M
  • Intuitive Surgical Operations, Inc.$59K
  • W. L. Gore & Associates, Inc.$12K
  • Davol Inc.$6K
  • Covidien LP$2K
  • Baxter Healthcare$2K
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$29,5102%
  • Speaking & faculty fees$135,75011%
  • Grants$1,0000%
  • Travel & lodging$92,2068%
  • Food & beverage$21,6152%
  • Education$905,99476%
  • Gifts$3330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,245,008 in reported general payments places this provider in the 95th percentile of 1,180 surgery providers in Illinois.

See all surgery providers in Illinois

Medicare billing

Part B allowed, 2024
$376,941
Medicare patients
576
Services billed
1,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase34$63,906
ZenpepLipase/Protease/Amylase11$27,915
SutabSod Sulf/Pot Chloride/Mag Sulf57$8,989
CholestyramineCholestyramine (With Sugar)30$1,253
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl54$789
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl30$435
Famotidine28$268
Pantoprazole Sodium20$250
Sucralfate18$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$326$63,90634 claims
Aimmune Therapeutics, Inc.Zenpep$151$27,91511 claims
Braintree Laboratories, Inc.Sutab$165$8,98957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,180 surgery providers in Illinois.

Other surgery in New Lenox

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →